Novavax Inc has a consensus price target of $54.43 based on the ratings of 7 analysts. The high is $168 issued by Cantor Fitzgerald on June 8, 2022. The low is $10 issued by TD Cowen on May 13, 2024. The 3 most-recent analyst ratings were released by B of A Securities, B. Riley Securities, and HC Wainwright & Co. on June 14, 2024, May 23, 2024, and May 13, 2024, respectively. With an average price target of $22 between B of A Securities, B. Riley Securities, and HC Wainwright & Co., there's an implied 30.42% upside for Novavax Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/14/2024 | Buy Now | 6.71% | B of A Securities | Alec Stranahan | $12 → $18 | Maintains | Neutral | Get Alert |
05/23/2024 | Buy Now | 71.91% | B. Riley Securities | Mayank Mamtani | $11 → $29 | Maintains | Buy | Get Alert |
05/13/2024 | Buy Now | 12.63% | HC Wainwright & Co. | Vernon Bernardino | → $19 | Reiterates | Buy → Buy | Get Alert |
05/13/2024 | Buy Now | -40.72% | TD Cowen | Brendan Smith | $5 → $10 | Maintains | Hold | Get Alert |
05/10/2024 | Buy Now | -28.86% | B of A Securities | Alec Stranahan | $4 → $12 | Upgrade | Underperform → Neutral | Get Alert |
03/01/2024 | Buy Now | 12.63% | HC Wainwright & Co. | Vernon Bernardino | $35 → $19 | Maintains | Buy | Get Alert |
02/23/2024 | Buy Now | -34.79% | B. Riley Securities | Mayank Mamtani | $12 → $11 | Maintains | Buy | Get Alert |
11/10/2023 | Buy Now | -28.86% | B. Riley Securities | Mayank Mamtani | $15 → $12 | Maintains | Buy | Get Alert |
08/10/2023 | Buy Now | 107.48% | HC Wainwright & Co. | Vernon Bernardino | → $35 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | Buy Now | -11.08% | B. Riley Securities | Mayank Mamtani | → $15 | Upgrade | Neutral → Buy | Get Alert |
05/10/2023 | Buy Now | 107.48% | HC Wainwright & Co. | Vernon Bernardino | $110 → $35 | Reiterates | → Buy | Get Alert |
03/01/2023 | Buy Now | -40.72% | B. Riley Securities | Mayank Mamtani | $29 → $10 | Downgrade | Buy → Neutral | Get Alert |
02/13/2023 | Buy Now | 552.09% | HC Wainwright & Co. | Vernon Bernardino | → $110 | Reiterates | → Buy | Get Alert |
01/02/2023 | Buy Now | 552.09% | HC Wainwright & Co. | Vernon Bernardino | $207 → $110 | Maintains | Buy | Get Alert |
10/14/2022 | Buy Now | 392.03% | B. Riley Securities | Mayank Mamtani | $126 → $83 | Maintains | Buy | Get Alert |
09/22/2022 | Buy Now | 60.06% | JP Morgan | Eric Joseph | $132 → $27 | Downgrade | Neutral → Underweight | Get Alert |
08/09/2022 | Buy Now | 552.09% | Cowen & Co. | Georgi Yordanov | $150 → $110 | Maintains | Outperform | Get Alert |
06/08/2022 | Buy Now | 895.92% | Cantor Fitzgerald | Charles Duncan | $146 → $168 | Maintains | Overweight | Get Alert |
05/20/2022 | Buy Now | — | B of A Securities | Alec Stranahan | — | Initiates | → Underperform | Get Alert |
04/26/2022 | Buy Now | 1103.4% | B. Riley Securities | Mayank Mamtani | $250 → $203 | Maintains | Buy | Get Alert |
03/03/2022 | Buy Now | 1127.11% | HC Wainwright & Co. | Vernon Bernardino | $294 → $207 | Maintains | Buy | Get Alert |
01/21/2022 | Buy Now | 789.21% | Cowen & Co. | Georgi Yordanov | → $150 | Initiates | → Outperform | Get Alert |
12/21/2021 | Buy Now | 1138.97% | JP Morgan | Eric Joseph | $172 → $209 | Maintains | Neutral | Get Alert |
The latest price target for Novavax (NASDAQ:NVAX) was reported by B of A Securities on June 14, 2024. The analyst firm set a price target for $18.00 expecting NVAX to rise to within 12 months (a possible 14.72% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Novavax (NASDAQ:NVAX) was provided by B of A Securities, and Novavax maintained their neutral rating.
The last upgrade for Novavax Inc happened on May 10, 2024 when B of A Securities raised their price target to $12. B of A Securities previously had an underperform for Novavax Inc.
The last downgrade for Novavax Inc happened on March 1, 2023 when B. Riley Securities changed their price target from $29 to $10 for Novavax Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novavax was filed on June 14, 2024 so you should expect the next rating to be made available sometime around June 14, 2025.
While ratings are subjective and will change, the latest Novavax (NVAX) rating was a maintained with a price target of $12.00 to $18.00. The current price Novavax (NVAX) is trading at is $15.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.